Simon et al reviewed the skeletal consequences of discontinuing HT and the specific treatment options for these women. [12] This analysis included 11 RCTs that reported data on BMD changes during and ...

Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

1. American College of Physicians recommends bisphosphonates for initial treatment for osteoporosis in males and postmenopausal females diagnosed with primary ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nonsteroidal ...

Professor of Medicine and Epidemiology and Preventive Medicine, Department of Medicine; Head, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine , Baltimore, ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

The unprecedented coronavirus disease 2019 (COVID-19) pandemic facilitated the rapid development and subsequent deployment of several novel and highly effective vaccines. However, the role of ...